Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 544Neoplasms 384Carcinoma, Non-Small-Cell Lung 325Colorectal Neoplasms 296Lung Neoplasms 237Prostatic Neoplasms 220Carcinoma, Hepatocellular 213Stomach Neoplasms 155Pancreatic Neoplasms 155Leukemia, Myeloid, Acute 141Uterine Cervical Neoplasms 132Multiple Myeloma 130Recurrence 120Rectal Neoplasms 114Ovarian Neoplasms 109Neoplasm Metastasis 105Squamous Cell Carcinoma of Head and Neck 98Head and Neck Neoplasms 91Triple Negative Breast Neoplasms 87Esophageal Neoplasms 84Glioblastoma 82Endometrial Neoplasms 80Small Cell Lung Carcinoma 79Brain Neoplasms 79Colonic Neoplasms 78Melanoma 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Hematologic Neoplasms 65Glioma 63Disease 60

Interventions

dalpiciclib 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × HR+/HER2- Advanced Breast Cancer × Clear all
NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Beijing 302 Hospital

Phase 2 Not yet recruiting
155 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Fujian Medical University

Phase NA Not yet recruiting
52 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡